Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis

Cao, Lanxiao; Xu, Tian; Zhao, Gaohua; Lv, Dayao; Lu, Jinyu; Zhao, Guohua

doi:10.1007/s00415-021-10724-1

Cited by 20 publications

(18 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lower but significant intraclass ROR supported the existence of a disease-related susceptibility to ICDs not sufficient to explain the disproportionality of TGAs, lurasidone [a recent antipsychotic for which a case of hypersexuality has already been recorded ( Reddy et al, 2018 )], and olanzapine and ziprasidone (limited to hyperphagia). The high proportion of aripiprazole-related ICD cases in which the primary indication for use was a mood disorder is in line with the hypothesis that depression may be a synergistic risk factor for impulsive-compulsive behaviors ( Cao et al, 2021 ).…”

Section: Discussionsupporting

confidence: 69%

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System

Fusaroli

Raschi

Giunchi

et al. 2022

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

Background The dopaminergic partial agonism of the so-called third-generation antipsychotics (TGAs: aripiprazole, brexpiprazole, cariprazine) is hypothesized to cause Impulse Control Disorders (ICDs). Relevant warnings by the Food and Drug Administration (FDA) were posted on aripiprazole (2016) and brexpiprazole (2018). Our study investigated the FDA Adverse Event Reporting System (FAERS) and the pharmacodynamic CHEMBL database to further characterize TGA-induced ICDs. Methods We downloaded and pre-processed the FAERS up to December 2020. We adapted Bradford Hill criteria to assess each TGA’s –and secondarily other antipsychotics’– causal role in inducing ICDs (pathological gambling, compulsive shopping, hyperphagia, hypersexuality), accounting for literature and disproportionality. ICDs clinical features were analyzed, and their pathogenesis investigated using receptor affinities. Results 2708 reports of TGA-related ICDs were found, primarily recording aripiprazole (2545 reports, 94%) among the drugs, and gambling (2018 reports, 75%) among the events. Bradford-Hill criteria displayed evidence for a causal role of each TGA, consistent across subpopulations and when correcting for biases. Significant disproportionalities also emerged for lurasidone with compulsive shopping, hyperphagia, and hypersexuality, and olanzapine and ziprasidone with hyperphagia. Time to onset varied between days and years, and positive dechallenge was observed in 20% cases. Frequently co-reported events were economic (50%), obsessive-compulsive (44%), and emotional conditions (34%). 5-HT1A emerged as an additional plausible pathogenetic mechanism. Conclusions We detected an association between TGAs and ICDs and identified a new signal for lurasidone. ICD characteristics are behavior-specific and may impact heavily on life. The role of 5-HT1A-agonism should be further explored.

show abstract

Section: Discussionsupporting

confidence: 69%

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System

Fusaroli

Raschi

Giunchi

et al. 2022

International Journal of Neuropsychopharmacology

View full text Add to dashboard Cite

show abstract

“…Regarding the effects of safinamide on ICD, a similar action to amantadine has been suggested. Even though several meta-analyses, which included cross-sectional studies, showed the use of amantadine as a factor related to ICD [28], several small-scale prospective interventional studies showed that pathological gambling and punding were improved by amantadine [29,30]. Amantadine enhances dopamine release and acts as an N-methyl-Daspartate receptor antagonist, and its anti-glutamatergic action may show benefits in ICD.…”

Section: Discussionmentioning

confidence: 99%

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson’s Disease: Online-Based Delphi Survey

Takeda

Tsuboi

Nomoto

et al. 2022

Parkinson's Disease

View full text Add to dashboard Cite

Background. Safinamide is a selective, reversible monoamine oxidase-B inhibitor with a sodium channel inhibitory effect. Published clinical evidence supports safinamide as an effective therapy for Parkinson’s disease (PD) with wearing-off. However, to date, no consensus recommendations have been available to guide physicians in Asia on the optimal use of safinamide in clinical practice. To summarize opinions on the optimal patient profile and methods of using safinamide in common clinical scenarios, Japanese movement disorder specialists with expertise in PD investigated the perspectives of neurologists and neurosurgeons. Methods. The Delphi panel approach was used to summarize the opinions of panelists. The panel comprised doctors from Japan with extensive clinical practice experience in the use of safinamide (n = 46 at the final round). The consensus was defined as 80% or more agreement between panelists for each scenario at the final round. Results. There was a high level of agreement that patients with the following symptoms are suitable for safinamide treatment such as bradykinesia (100%), rigidity (95.7%), and/or gait disorder (89.1%) based on motor symptoms and PD-related pain (97.8%) and/or depression or apathy (93.5%) based on non-motor symptoms. Morning-off (95.7%), but not dyskinesia (71.7%), also reached consensus. The use of high-dose safinamide (100 mg/day) was recommended when the improvement in PD symptoms is insufficient and increasing the doses of other anti-PD medications is difficult (97.8%) or when the abovementioned non-motor symptoms adversely affect daily life (93.5%). Conclusions. This report provides expert perspectives on the use of safinamide for a wide range of clinical scenarios in Japan.

show abstract

“…80 Demographic correlates include male sex, younger age at PD onset, and longer PD duration. 81 Dopamine agonist (DA) treatment is the strongest ICD predictor 78 80 ; higher dose levodopa, 78 amantadine, 82 and selective MAO-B inhibitors 83 have also been associated with ICD to a lesser extent. DDS is most associated with higher levodopa doses.…”

Section: Impulse Control Disorders and Related Behaviorsmentioning

confidence: 99%

“…Recent national multi-site studies reported longitudinal cross-sectional prevalence rates of 25-30%79 and a cumulative incidence rate of 46% 80. Demographic correlates include male sex, younger age at PD onset, and longer PD duration 81. Dopamine agonist (DA) treatment is the strongest ICD predictor7880; higher dose levodopa,78 amantadine,82 and selective MAO-B inhibitors83 have also been associated with ICD to a lesser extent.…”

Section: Epidemiology and Neurobiologymentioning

confidence: 99%

Management of psychiatric and cognitive complications in Parkinson’s disease

Weintraub

Aarsland

Biundo

et al. 2022

BMJ

View full text Add to dashboard Cite

Neuropsychiatric symptoms (NPSs) such as affective disorders, psychosis, behavioral changes, and cognitive impairment are common in Parkinson’s disease (PD). However, NPSs remain under-recognized and under-treated, often leading to adverse outcomes. Their epidemiology, presentation, risk factors, neural substrate, and management strategies are incompletely understood. While psychological and psychosocial factors may contribute, hallmark PD neuropathophysiological changes, plus the associations between exposure to dopaminergic medications and occurrence of some symptoms, suggest a neurobiological basis for many NPSs. A range of psychotropic medications, psychotherapeutic techniques, stimulation therapies, and other non-pharmacological treatments have been studied, are used clinically, and are beneficial for managing NPSs in PD. Appropriate management of NPSs is critical for comprehensive PD care, from recognizing their presentations and timing throughout the disease course, to the incorporation of different therapeutic strategies (ie, pharmacological and non-pharmacological) that utilize a multidisciplinary approach.

show abstract

Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis

Cited by 20 publications

References 58 publications

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System

Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson’s Disease: Online-Based Delphi Survey

Management of psychiatric and cognitive complications in Parkinson’s disease

Contact Info

Product

Resources

About